Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Targetoid hemosiderotic hemangioma]

C Perrin1, S Rodot, J P Ortonne

  • 1Service d'Anatomie Pathologique, Hôpital Pasteur, Nice.

Annales De Dermatologie Et De Venereologie
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Regorafenib as maintenance therapy after first-line doxorubicin-based chemotherapy in advanced non-adipocytic soft tissue sarcomas patients: a double-blind randomised trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Assessment of the current and emerging criteria for the histopathological classification of lung neuroendocrine tumours in the lungNENomics project.

ESMO open·2024
Same author

Improved nationwide survival of sarcoma patients with a network of reference centers.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Sclerosing Epithelioid Fibrosarcoma (SEF) versus Low Grade Fibromyxoid Sarcoma (LGFMS): Presentation and outcome in the nationwide NETSARC+ series of 330 patients over 13 years.

European journal of cancer (Oxford, England : 1990)·2023
Same author

Epithelioid hemangio-endothelioma (EHE) in NETSARC: The nationwide series of 267 patients over 12 years.

European journal of cancer (Oxford, England : 1990)·2023
Same author

Regorafenib in patients with relapsed advanced or metastatic chordoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study.

ESMO open·2023

Targetoid hemosiderotic hemangioma (THH) is a rare vascular disorder. This case highlights unique histological features and discusses its differential diagnosis with other vascular tumors.

Area of Science:

  • Dermatopathology
  • Vascular Neoplasms

Background:

  • Targetoid hemosiderotic hemangioma (THH) is a rare vascular disorder.
  • Characterized by a violaceous papule with an ecchymotic ring, typically under 1 cm.
  • Histological hallmarks include hobnail endothelial cells, papillary projections, and hemosiderin.

Observation:

  • Presents a case of THH with distinct morphological features.
  • Notable findings include prominent lymphocytic infiltrate and intraluminal lymphocytes.
  • Scarcity of siderophages and a retiform pattern were observed.

Findings:

  • The case exhibited a predilection for hair erector muscles and eccrine ducts.
  • Detailed histological analysis revealed specific cellular and vascular patterns.
  • The observed features contribute to understanding THH variations.

Related Experiment Videos

Implications:

  • Discusses the differential diagnosis of THH, Kaposi sarcoma, lymphangioendothelioma, and retiform hemangioendothelioma.
  • Highlights the importance of careful histological evaluation for accurate diagnosis.
  • Contributes to the literature on rare vascular disorders and their distinctions.